Literature DB >> 15008985

Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

E Schmidt1, B Wehr, E M Tabengwa, S Reimer, E-B Bröcker, D Zillikens.   

Abstract

In bullous pemphigoid (BP), the binding of BP180-specific antibodies to their hemidesmosomal target antigen is not sufficient for blister formation, but must be accompanied by the release of proteases. Using plasminogen activator (PA) knock-out mice, the PA system has previously been shown to be a prerequisite for blister formation in experimental murine BP. Here, we found elevated levels of plasmin and tPA, but not of uPA, in blister fluid from BP patients (n = 7) compared to blisters from patients with toxic epidermal necrolysis (n = 4) and suction blisters in healthy controls (n = 7). Subsequently, we addressed the question whether keratinocytes release PA in response to the binding of anti-BP180 antibodies. Treatment of cultured normal human keratinocytes with BP IgG, but not with control IgG, led to both increased protein and mRNA levels of tPA, but not of uPA, as determined by ELISA and RT-PCR, respectively. The specificity of this finding was confirmed using BP180-deficient keratinocytes from a patient with generalized atrophic benign epidermolysis bullosa, where no tPA release was observed after stimulation with BP IgG. Our results show the elevated expression and release of tPA from normal human keratinocytes upon stimulation with antibodies to human BP180. Keratinocytes, by secreting tPA, may thus play an active role in blister formation of BP.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008985      PMCID: PMC1808969          DOI: 10.1111/j.1365-2249.2004.02401.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180.

Authors:  G J Giudice; D J Emery; L A Diaz
Journal:  J Invest Dermatol       Date:  1992-09       Impact factor: 8.551

2.  Urokinase and tissue type plasminogen activators in human keratinocyte culture.

Authors:  P J Jensen; M John; J Baird
Journal:  Exp Cell Res       Date:  1990-03       Impact factor: 3.905

3.  Chromogenic peptide substrates. Their use for the assay of factors in the fibrinolytic and the plasma kallikrein-kinin systems.

Authors:  P Friberger
Journal:  Scand J Clin Lab Invest Suppl       Date:  1982

4.  Isolation of a human epidermal cDNA corresponding to the 180-kD autoantigen recognized by bullous pemphigoid and herpes gestationis sera. Immunolocalization of this protein to the hemidesmosome.

Authors:  L A Diaz; H Ratrie; W S Saunders; S Futamura; H L Squiquera; G J Anhalt; G J Giudice
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

5.  Production of rabbit antibodies against carboxy-terminal epitopes encoded by bullous pemphigoid cDNA.

Authors:  T Tanaka; N J Korman; H Shimizu; R A Eady; V Klaus-Kovtun; K Cehrs; J R Stanley
Journal:  J Invest Dermatol       Date:  1990-05       Impact factor: 8.551

6.  mRNA for tissue-type plasminogen activator is present in lesional epidermis from patients with psoriasis, pemphigus, or bullous pemphigoid, but is not detected in normal epidermis.

Authors:  J Baird; G S Lazarus; D Belin; J D Vassalli; N Busso; P Gubler; P J Jensen
Journal:  J Invest Dermatol       Date:  1990-11       Impact factor: 8.551

7.  The autoimmune blistering skin disease bullous pemphigoid. The presence of plasmin/alpha 2-antiplasmin complexes in skin blister fluid indicates plasmin generation in lesional skin.

Authors:  M D Kramer; J Reinartz
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  An immunohistochemical study of the distribution of plasminogen and plasminogen activators in bullous pemphigoid.

Authors:  V A Venning; F Wojnarowska; S Cederholm-Williams
Journal:  Clin Exp Dermatol       Date:  1993-03       Impact factor: 3.470

9.  Epidermal plasminogen activator is abnormal in cutaneous lesions.

Authors:  P J Jensen; J Baird; S Morioka; S Lessin; G S Lazarus
Journal:  J Invest Dermatol       Date:  1988-06       Impact factor: 8.551

10.  Enhanced association of plasminogen/plasmin with lesional epidermis of bullous pemphigoid.

Authors:  H M Gissler; M M Simon; M D Kramer
Journal:  Br J Dermatol       Date:  1992-09       Impact factor: 9.302

View more
  9 in total

1.  Comparison of reactivity and epitope recognition between sera from American and Italian patients with oral pemphigoid.

Authors:  M Mignogna; A Lanza; L Rossiello; V Ruocco; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 2.  The pathophysiology of bullous pemphigoid.

Authors:  Michael Kasperkiewicz; Detlef Zillikens
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

3.  14-3-3 sigma isoform interacts with the cytoplasmic domain of the transmembrane BP180 in keratinocytes.

Authors:  Yunyuan Li; Xiaoyue Lin; Ruhangiz T Kilani; Jonathan C R Jones; Aziz Ghahary
Journal:  J Cell Physiol       Date:  2007-09       Impact factor: 6.384

4.  Prothrombotic state and impaired fibrinolysis in bullous pemphigoid, the most frequent autoimmune blistering disease.

Authors:  A V Marzano; A Tedeschi; I Polloni; C Crosti; M Cugno
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

5.  Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid.

Authors:  Ágnes Kinyó; Anita Hanyecz; Zsuzsanna Lengyel; Dalma Várszegi; Péter Oláh; Csaba Gyömörei; Endre Kálmán; Tímea Berki; Rolland Gyulai
Journal:  J Clin Med       Date:  2021-04-28       Impact factor: 4.241

6.  Autoantibody Profile of a Cohort of 54 Italian Patients with Linear IgA Bullous Dermatosis: LAD-1 Denoted as a Major Auto-antigen of the Lamina Lucida Subtype.

Authors:  Emanuele Cozzani; Giovanni Di Zenzo; Giulia Gasparini; Adele Salemme; Arianna Fay Agnoletti; Camilla Vassallo; Marzia Caproni; Emiliano Antiga; Angelo V Marzano; Riccardo Cavalli; Corrado Ocella; Clara de Simone; Aurora Parodi
Journal:  Acta Derm Venereol       Date:  2020-02-29       Impact factor: 3.875

7.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875

Review 8.  Proteases in Pemphigoid Diseases.

Authors:  Sho Hiroyasu; Christopher T Turner; Katlyn C Richardson; David J Granville
Journal:  Front Immunol       Date:  2019-06-26       Impact factor: 7.561

Review 9.  Type XVII collagen: Relevance of distinct epitopes, complement-independent effects, and association with neurological disorders in pemphigoid disorders.

Authors:  Bianca Opelka; Enno Schmidt; Stephanie Goletz
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.